Cargando…
Efficacy of inverso isomer of CendR peptide on tumor tissue penetration
The dense extracellular matrix and high interstitial fluid pressure of tumor tissues prevent the ability of anti-tumor agents to penetrate deep into the tumor parenchyma for treatment effects. C-end rule (CendR) peptides can enhance the permeability of tumor blood vessels and tumor tissues via bindi...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6146380/ https://www.ncbi.nlm.nih.gov/pubmed/30245969 http://dx.doi.org/10.1016/j.apsb.2018.06.006 |
_version_ | 1783356385072775168 |
---|---|
author | Wang, Ruifeng Shen, Qing Li, Xue Xie, Cao Lu, Weiyue Wang, Songli Wang, Jing Wang, Dongli Liu, Min |
author_facet | Wang, Ruifeng Shen, Qing Li, Xue Xie, Cao Lu, Weiyue Wang, Songli Wang, Jing Wang, Dongli Liu, Min |
author_sort | Wang, Ruifeng |
collection | PubMed |
description | The dense extracellular matrix and high interstitial fluid pressure of tumor tissues prevent the ability of anti-tumor agents to penetrate deep into the tumor parenchyma for treatment effects. C-end rule (CendR) peptides can enhance the permeability of tumor blood vessels and tumor tissues via binding to neuropilin-1 (NRP-1), thus aiding in drug delivery. In this study, we selected one of the CendR peptides (sequence RGERPPR) as the parent l-peptide and substituted d-amino acids for the l-amino acids to synthesize its inverso peptide (D)(RGERPPR). We investigated the NRP-1 binding activity and tumor-penetrating ability of (D)(RGERPPR). We found that the binding affinity of (D)(RGERPPR) with NRP-1 and the cellular uptake was significantly higher than that of RGERPPR. Evans Blue tests revealed that (D)(RGERPPR) exhibited improved tumor-penetrating ability in C6, U87 and A549 tumor-bearing nude mice. Using nude mice bearing A549 xenograft tumors as a model, we found that the rate of tumor growth in the group co-administered with (D)(RGERPPR) and gemcitabine (Gem) was significantly lower than the gemcitabine-treated group with a tumor suppression rate (TSR%) of 55.4%. Together, our results demonstrate that (D)(RGERPPR) is a potential tumor-penetrating peptide. |
format | Online Article Text |
id | pubmed-6146380 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-61463802018-09-21 Efficacy of inverso isomer of CendR peptide on tumor tissue penetration Wang, Ruifeng Shen, Qing Li, Xue Xie, Cao Lu, Weiyue Wang, Songli Wang, Jing Wang, Dongli Liu, Min Acta Pharm Sin B Original article The dense extracellular matrix and high interstitial fluid pressure of tumor tissues prevent the ability of anti-tumor agents to penetrate deep into the tumor parenchyma for treatment effects. C-end rule (CendR) peptides can enhance the permeability of tumor blood vessels and tumor tissues via binding to neuropilin-1 (NRP-1), thus aiding in drug delivery. In this study, we selected one of the CendR peptides (sequence RGERPPR) as the parent l-peptide and substituted d-amino acids for the l-amino acids to synthesize its inverso peptide (D)(RGERPPR). We investigated the NRP-1 binding activity and tumor-penetrating ability of (D)(RGERPPR). We found that the binding affinity of (D)(RGERPPR) with NRP-1 and the cellular uptake was significantly higher than that of RGERPPR. Evans Blue tests revealed that (D)(RGERPPR) exhibited improved tumor-penetrating ability in C6, U87 and A549 tumor-bearing nude mice. Using nude mice bearing A549 xenograft tumors as a model, we found that the rate of tumor growth in the group co-administered with (D)(RGERPPR) and gemcitabine (Gem) was significantly lower than the gemcitabine-treated group with a tumor suppression rate (TSR%) of 55.4%. Together, our results demonstrate that (D)(RGERPPR) is a potential tumor-penetrating peptide. Elsevier 2018-09 2018-06-30 /pmc/articles/PMC6146380/ /pubmed/30245969 http://dx.doi.org/10.1016/j.apsb.2018.06.006 Text en © 2018 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original article Wang, Ruifeng Shen, Qing Li, Xue Xie, Cao Lu, Weiyue Wang, Songli Wang, Jing Wang, Dongli Liu, Min Efficacy of inverso isomer of CendR peptide on tumor tissue penetration |
title | Efficacy of inverso isomer of CendR peptide on tumor tissue penetration |
title_full | Efficacy of inverso isomer of CendR peptide on tumor tissue penetration |
title_fullStr | Efficacy of inverso isomer of CendR peptide on tumor tissue penetration |
title_full_unstemmed | Efficacy of inverso isomer of CendR peptide on tumor tissue penetration |
title_short | Efficacy of inverso isomer of CendR peptide on tumor tissue penetration |
title_sort | efficacy of inverso isomer of cendr peptide on tumor tissue penetration |
topic | Original article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6146380/ https://www.ncbi.nlm.nih.gov/pubmed/30245969 http://dx.doi.org/10.1016/j.apsb.2018.06.006 |
work_keys_str_mv | AT wangruifeng efficacyofinversoisomerofcendrpeptideontumortissuepenetration AT shenqing efficacyofinversoisomerofcendrpeptideontumortissuepenetration AT lixue efficacyofinversoisomerofcendrpeptideontumortissuepenetration AT xiecao efficacyofinversoisomerofcendrpeptideontumortissuepenetration AT luweiyue efficacyofinversoisomerofcendrpeptideontumortissuepenetration AT wangsongli efficacyofinversoisomerofcendrpeptideontumortissuepenetration AT wangjing efficacyofinversoisomerofcendrpeptideontumortissuepenetration AT wangdongli efficacyofinversoisomerofcendrpeptideontumortissuepenetration AT liumin efficacyofinversoisomerofcendrpeptideontumortissuepenetration |